Peptide News Digest
Evidence Brief 9 min read

Eating Too Little on Ozempic, Wegovy, Mounjaro or Zepbound: Calorie, Fiber, Vitamin D and Iron Gaps

A 14-patient English study found average intake near 1,230 calories a day and wide shortfalls in fiber, vitamin D, iron and produce. Records data on anemia, a small lean mass trial and the 2025 nutrition advisory help show who should watch for it.

Key points

  • In a BMJ Nutrition, Prevention & Health study of 14 patients on GLP-1 or GIP/GLP-1 drugs at one English general practice, average intake over two recalled days was 1,231 calories, 58.5% of estimated needs, and three people ate under 800 calories a day
  • More than three-quarters were below two-thirds of the UK reference intake for fiber and for vitamin D, half for iron, and none ate the recommended 400 grams of fruit and vegetables, while protein averaged 153% of the reference
  • The authors call the 14-person study hypothesis-generating and say no drug-specific nutritional monitoring framework exists; participants reported dizziness, low blood pressure and thin follow-up
  • In a TriNetX records study by researchers in Taiwan, covering 67,608 matched pairs with type 2 diabetes, 2.13% of tirzepatide starters and 2.84% of GLP-1 starters were diagnosed with iron, B12 or folate deficiency anemia within a year (hazard ratio 0.88); the study had no untreated comparison group
  • The 2025 joint nutrition advisory says GLP-1 drugs cut energy intake by 16% to 39% versus placebo and flags nutrient risk especially below 1,200 calories a day for women and 1,800 for men
  • In a four-month open-label Moscow trial of 52 adults with type 2 diabetes, semaglutide plus diet produced more weight loss than diet alone (8.65% vs 4.55%), and lean mass fell by about 0.4 kg per kilogram lost in both groups, measured by BIA
  • Zepbound and Wegovy labels link low blood pressure and acute kidney injury to dehydration from nausea, vomiting or diarrhea, and advise patients to drink fluids and report persistent symptoms

Fourteen patients at one English practice kept two-day food records

Researchers from the University of Oxford and the NNEdPro Global Institute for Food, Nutrition and Health asked 14 patients at one general practice in England to recall everything they ate over two days. Each had been prescribed a GLP-1 receptor agonist or a dual GIP/GLP-1 drug, the class that includes Ozempic and Wegovy (semaglutide) and Mounjaro and Zepbound (tirzepatide). Ten were private patients and four were NHS patients. The team logged the food in myfood24, an online diet-recall tool, and compared 28 nutrients against UK reference values. The paper appeared in BMJ Nutrition, Prevention & Health on November 17, 2026, and our November 19 digest covered it.

According to the BMJ's press summary:

  • Average intake was 1,231 calories a day, 58.5% of the estimated energy requirement for each person's sex. Three people ate under 800 calories a day.
  • More than three-quarters fell below two-thirds of the UK reference nutrient intake (RNI) for fiber, and the same was true for vitamin D. Iron intake was below that threshold in half of them.
  • Eight of the 14 were below two-thirds of the RNI for at least three of six nutrients the team focused on: fiber, iron, vitamin D, potassium, protein and magnesium.
  • None reached the recommended 400 grams (about 14 ounces, or "5-a-day") of fruit and vegetables.
  • Ultra-processed foods supplied 33% of calories on average and 84% for one participant.

This is a very small study from a single practice in what the summary describes as a relatively affluent area. The authors call it hypothesis-generating. It is observational, the summary describes no comparison group of people off the drugs, and two days of recalled eating is a short window, so it cannot show that the medicines caused any shortfall. We could not open the full paper, so the figures above come from the BMJ summary.

Protein was the nutrient they did get

Protein averaged 153% of the RNI, and only one participant fell short. Protein gets much of the attention in advice for GLP-1 users because it helps protect muscle, and the 2025 joint advisory discussed below calls sufficient protein a priority (our protein and resistance training guide covers it). In this group the shortfalls were in fiber, vitamin D, iron and produce instead.

People also described changes beyond the plate. Some said "food noise," the constant background chatter about food, went quiet, and that they drank less alcohol (our food noise explainer looks at that evidence). Others said they ate socially less often. Many said follow-up was thin. The summary reports that inadequate medication reviews left side effects such as dizziness and low blood pressure unmanaged, and that some people turned to online peer groups for advice.

"No drug-specific nutritional monitoring framework exists," the researchers write. They point out that standard UK advice, built on the Eatwell Guide, was not designed for people taking these drugs.

A food record measures intake; a blood test measures deficiency

The BMJ study counted what people ate. It did not measure what was in their blood, and the two can differ. Vitamin D is the clearest case. MedlinePlus, the National Library of Medicine's consumer site, notes that the body makes vitamin D when skin is exposed to the sun, that most people meet at least some of their needs that way, and that very few foods contain it naturally. A low vitamin D intake on a food record, by itself, does not tell you someone's blood level.

Iron deficiency anemia is diagnosed with blood work, according to MedlinePlus: a complete blood count along with tests of serum iron, total iron-binding capacity and ferritin. Its listed causes include eating too little iron, heavy or frequent periods, and poor absorption from conditions such as celiac disease or gastric bypass surgery.

A second paper, posted online the same day, looked at diagnoses instead of diets. Researchers at Chi Mei Medical Center in Taiwan used TriNetX, a large research database of patient records, to find adults with type 2 diabetes and overweight or obesity who started tirzepatide or a GLP-1 drug between January 2022 and August 2026. They used propensity score matching, a statistical method that pairs people with similar characteristics, to build two groups of 67,608 each. Then they counted new diagnoses of iron, vitamin B12 or folate deficiency anemia in the first year.

Within that year, 2.13% of tirzepatide starters and 2.84% of GLP-1 starters received one of those diagnoses. The hazard ratio, which compares how often an event happens over time in two groups, was 0.88 (95% confidence interval 0.83 to 0.95). In absolute terms the gap is 0.71 percentage points. Most of it came from iron deficiency anemia (hazard ratio 0.87). The B12 and folate results were inconclusive.

Both groups took a drug from the same family, so the study cannot say whether either one raises anemia risk compared with no drug at all. The authors write in Diabetes Research and Clinical Practice that leftover confounding and differences in follow-up and diagnosis limit any causal reading. What it does show is narrower. In this records population, a recorded nutritional anemia diagnosis within a year was not rare, at roughly 2 to 3 people in 100. The study also excluded anyone with past bariatric surgery or a prior nutritional anemia, two groups the 2025 advisory singles out for extra testing.

How far intake drops, and where the 2025 advisory draws a line

In 2025, the American College of Lifestyle Medicine, the American Society for Nutrition, the Obesity Medicine Association and The Obesity Society published a joint advisory on nutrition during GLP-1 therapy in the American Journal of Clinical Nutrition. It cites studies in which GLP-1 drugs cut energy intake by 16% to 39% compared with placebo. A drop that large and that fast, it says, can leave people short of vitamins and minerals, "especially at energy intakes <1200 kcal/d for females and <1800 kcal/d for males." Its examples of nutrients of concern are iron, calcium, magnesium, zinc, and vitamins A, D, E, K, B1, B12 and C.

The BMJ group's 1,231-calorie average mixes men and women, so it does not line up neatly with those cutoffs. The three people eating under 800 calories were far below both.

The advisory lists signs of frank deficiency: fatigue beyond what is expected, excessive hair loss, flaky or itchy skin, muscle weakness, poor wound healing and unusual bruising. Those overlap with complaints covered in our briefs on fatigue and hair and nail changes, which have other possible causes too.

It also describes a loop some people fall into: nausea makes them skip food, skipping food worsens the nausea, and they eat even less. Its suggestions include small, regular meals, smoothies, yogurt, cottage cheese or soups when heavier food is unappealing, and an alarm or other reminder to eat if changing foods is not enough. On supplements, it says products such as vitamin D, calcium, B12 or a multivitamin-mineral tablet "can be proactively considered for at-risk nutrients," at doses tailored to each person. It recommends regular re-checks of diet, hydration and nutrient levels during treatment, for example with food logs or food photos.

Dizziness, low blood pressure and fluid loss

Some BMJ participants reported dizziness and low blood pressure. The study does not explain why, but the U.S. prescribing information for Zepbound and Wegovy connects low blood pressure with the drugs' stomach side effects.

In a pool of two Zepbound weight-loss trials, hypotension (low blood pressure) occurred in 1.6% of people on the drug and 0.1% on placebo. The label says it "also occurred in association with gastrointestinal adverse events and dehydration." Wegovy's label reports hypotension-related reactions in 1.3% of adults on the drug versus 0.4% on placebo, and fainting in 0.8% versus 0.2%, with some reactions tied to stomach side effects and fluid loss. Both labels say low blood pressure was more frequent in people who also took blood pressure medicine.

The labels also warn about acute kidney injury. Most reported cases came after nausea, vomiting or diarrhea caused dehydration, and some needed dialysis. The medication guides tell patients that drinking fluids helps reduce the chance of dehydration, and to call their provider right away if nausea, vomiting or diarrhea does not go away.

Lean mass tracked weight loss in a small Moscow trial

Eating very little raises a second worry: losing muscle along with fat. A trial published November 17 in the Almanac of Clinical Medicine adds one data point. Researchers at the Moscow Regional Research and Clinical Institute (MONIKI) randomly assigned adults with type 2 diabetes and obesity to semaglutide (up to 1 mg a week, below the 2.4 mg Wegovy dose) plus an individualized diet, or to the diet alone. The trial was open-label, meaning everyone knew who was getting the drug. After four months, 52 people were analyzed: 31 on semaglutide and 21 on diet alone.

Weight fell 8.65% in the semaglutide group and 4.55% with diet alone, an adjusted difference of 4.09 percentage points. The semaglutide group lost more lean mass, but in proportion to its larger weight loss. In both groups, each extra kilogram of weight lost came with roughly 0.4 kg less lean mass (0.37 kg with semaglutide, 0.43 kg with diet). Lean mass as a share of body weight rose by about 2.8 percentage points in each group. The authors found no evidence of disproportionate lean mass loss with semaglutide over four months and wrote that steps to preserve muscle and bone are warranted with any clinically significant weight loss.

Lean mass is a broader category than muscle. The joint advisory describes lean body mass as muscle plus other nonfat tissue and estimates that muscle makes up about half of it. The Moscow team measured body composition with bioelectrical impedance analysis (BIA). The advisory calls BIA practical at the point of care and describes DXA scanning as a gold standard, and it notes that both measure muscle mass but not muscle quality or function. The trial abstract reports no data on nutrient intake. For the larger body composition trials, see our lean mass brief; for fracture data, see the bone health brief.

Who has the most reason to watch their intake

None of these studies identifies who is most likely to undereat on these drugs. The guidance documents do name groups that deserve a closer look:

  • People eating far less than before, especially anyone near or below the advisory's 1,200-calorie (women) or 1,800-calorie (men) marks, or skipping meals because of nausea.
  • People with a history of a very low-calorie diet, bariatric surgery, celiac disease, another inflammatory condition that predisposes to deficiency, or a previous nutrient deficiency. The advisory says these may call for extra assessment or lab tests before starting.
  • People with heavy, long or frequent periods, a cause of iron deficiency anemia listed by MedlinePlus.
  • People taking blood pressure medicine, given the label data on low blood pressure, and people with or at risk for kidney problems, whom the advisory says should be counseled on avoiding dehydration and have kidney function monitored.
  • Older adults, and people who get little physical activity or protein. The advisory says the effects of weight loss on muscle and bone are a particular concern for them.
  • People with a past eating disorder. The advisory calls restrictive eating disorders a general contraindication to GLP-1 use and recommends referral to specialists first; our eating disorders brief covers screening.

The advisory also lists food and nutrition insecurity among the things clinicians should screen for, and it says drug access, food insecurity and cooking and nutrition knowledge all affect whether obesity care with these drugs is equitable.

Questions to bring to a prescriber or dietitian

The joint advisory lists counseling from a registered dietitian nutritionist among its supportive strategies. These questions draw on the advisory, the drug labels and the BMJ study:

  • How much am I eating now compared with before I started, and is that enough for me? Would a week of food logs or food photos help us check?
  • Can you refer me to a registered dietitian, and does my plan or the prescribing service cover it?
  • Given my history, should I have blood tests before or during treatment, such as a complete blood count, ferritin, vitamin B12 or vitamin D? Our lab testing guide lists common panels.
  • My diet is now low in fiber, fruit and vegetables. What foods would fill those gaps, and is any supplement worth considering for me?
  • I feel dizzy or lightheaded when I stand up. Could that be dehydration, or my blood pressure medicine adding to the drug's effect?
  • Nausea is stopping me from eating. Should my dose increase wait, and what should I do if vomiting or diarrhea does not stop?
  • How will we check whether I am losing muscle: BIA, a DXA scan, or simple strength tests such as standing up from a chair?

Updates and corrections

No corrections yet.

Limitations

  • The BMJ study included only 14 people at one practice in a relatively affluent area, used two days of recalled intake, and described no comparison group; we could not access the full paper, so its figures come from the BMJ press summary
  • Dietary intake below a reference value does not establish a deficiency; blood levels were not reported in the BMJ summary, and vitamin D is also made in skin exposed to sunlight
  • The Chi Mei anemia study counted recorded diagnoses, compared two drug groups rather than drug versus no drug, and was limited to adults with type 2 diabetes; the authors note residual confounding
  • The Moscow trial was open-label, small, four months long, used semaglutide up to 1 mg rather than weight-loss doses, and measured lean mass by BIA, which does not separate muscle from other nonfat tissue or measure muscle function
  • Label rates of low blood pressure come from clinical trials and cannot explain the specific dizziness reported by BMJ participants
  • The 2025 advisory's calorie thresholds and supplement suggestions are expert guidance, not results from trials in GLP-1 users

Citations

  1. 1.
  2. 2.
  3. 3.
  4. 4.
  5. 5.
  6. 6.
  7. 7.
  8. 8.
  9. 9.

Peptides in this article

Full peptide profiles with evidence levels, dosing data, and safety notes live on peptidelist.org.

Related insights